2Department of Biochemistry, Istanbul University Institute of Oncology, Istanbul-Turkey
3Department of General Surgery, Gelişim University Faculty of Health Sciences, Istanbul-Turkey
4Department of General Surgery, Istanbul University Institute of Oncology, Istanbul-Turkey DOI : 10.5505/tjo.2021.2697 OBJECTIVE
Evaluation of the nectin-2 and nectin-4 protein and mRNA expression levels is aimed in this study, with concerning diagnostic and predictive value in breast cancer patients.
METHODS
Sixty patients with pathologically and radiologically verified breast cancer who were treated at the Istanbul
University, Institute of Oncology, between 2017 and 2018 are included in the study. Circulating
nectin-2 and nectin-4 protein levels were evaluated by solid-phase enzyme-linked immunosorbent assay
(Abbkine Scientific Co., Ltd.). For analyzing nectin-2- and nectin-4-specific mRNA in sera of the
patients, circulating cell-free RNA was extracted from serum using a monophasic phenol and guanidine
thiocyanate solution (Roche, Mannheim, Germany), according to the manufacturer"s protocol.
RESULTS
The median age of patients was 53 years. The mean tumor size was 30.21±17.32 mm. Forty-one patients
were in the luminal group. Lymph node involvement was detected in 25 patients. The nectin-4 expression
level was statistically significantly higher in those with Ki-67 ?30 and those with positive distant
metastasis compared to the other group. In addition, nectin-2 expression was higher in patients with
Grade 3 tumors.
CONCLUSION
High levels of nectin-2 and nectin-4 expression in the serum of patients correlate with poor disease
characteristics of breast cancer.